Literature DB >> 25124554

Liver X receptor β activation induces pyroptosis of human and murine colon cancer cells.

V Derangère1, A Chevriaux2, F Courtaut3, M Bruchard3, H Berger3, F Chalmin3, S Z Causse4, E Limagne3, F Végran3, S Ladoire1, B Simon5, W Boireau5, A Hichami3, L Apetoh1, G Mignot4, F Ghiringhelli1, C Rébé2.   

Abstract

Liver X receptors (LXRs) have been proposed to have some anticancer properties, through molecular mechanisms that remain elusive. Here we report for the first time that LXR ligands induce caspase-1-dependent cell death of colon cancer cells. Caspase-1 activation requires Nod-like-receptor pyrin domain containing 3 (NLRP3) inflammasome and ATP-mediated P2 × 7 receptor activation. Surprisingly, LXRβ is mainly located in the cytoplasm and has a non-genomic role by interacting with pannexin 1 leading to ATP secretion. Finally, LXR ligands have an antitumoral effect in a mouse colon cancer model, dependent on the presence of LXRβ, pannexin 1, NLRP3 and caspase-1 within the tumor cells. Our results demonstrate that LXRβ, through pannexin 1 interaction, can specifically induce caspase-1-dependent colon cancer cell death by pyroptosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25124554      PMCID: PMC4227150          DOI: 10.1038/cdd.2014.117

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  30 in total

Review 1.  Biological roles of liver X receptors in immune cells.

Authors:  Mónica Pascual-García; Annabel F Valledor
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2012-06-14       Impact factor: 4.291

2.  The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation.

Authors:  T Fernandes-Alnemri; J Wu; J-W Yu; P Datta; B Miller; W Jankowski; S Rosenberg; J Zhang; E S Alnemri
Journal:  Cell Death Differ       Date:  2007-06-29       Impact factor: 15.828

3.  Revisited BIA-MS combination: entire "on-a-chip" processing leading to the proteins identification at low femtomole to sub-femtomole levels.

Authors:  W Boireau; A Rouleau; G Lucchi; P Ducoroy
Journal:  Biosens Bioelectron       Date:  2008-07-01       Impact factor: 10.618

4.  Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases.

Authors:  Jeremy Dupaul-Chicoine; Garabet Yeretssian; Karine Doiron; Kirk S B Bergstrom; Christian R McIntire; Philippe M LeBlanc; Charles Meunier; Claire Turbide; Philippe Gros; Nicole Beauchemin; Bruce A Vallance; Maya Saleh
Journal:  Immunity       Date:  2010-03-11       Impact factor: 31.745

5.  Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis.

Authors:  Faraaz B Chekeni; Michael R Elliott; Joanna K Sandilos; Scott F Walk; Jason M Kinchen; Eduardo R Lazarowski; Allison J Armstrong; Silvia Penuela; Dale W Laird; Guy S Salvesen; Brant E Isakson; Douglas A Bayliss; Kodi S Ravichandran
Journal:  Nature       Date:  2010-10-14       Impact factor: 49.962

6.  The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer.

Authors:  Irving C Allen; Erin McElvania TeKippe; Rita-Marie T Woodford; Joshua M Uronis; Eda K Holl; Arlin B Rogers; Hans H Herfarth; Christian Jobin; Jenny P-Y Ting
Journal:  J Exp Med       Date:  2010-04-12       Impact factor: 14.307

7.  Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.

Authors:  J M Kokontis; N Hay; S Liao
Journal:  Mol Endocrinol       Date:  1998-07

8.  The oxysterol receptor LXR inhibits proliferation of human breast cancer cells.

Authors:  Lise-Lotte Vedin; Sebastian A Lewandowski; Paolo Parini; Jan-Ake Gustafsson; Knut R Steffensen
Journal:  Carcinogenesis       Date:  2009-01-23       Impact factor: 4.944

9.  Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells.

Authors:  Junichi Fukuchi; John M Kokontis; Richard A Hiipakka; Chih-Pin Chuu; Shutsung Liao
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

Review 10.  Purines, purinergic receptors, and cancer.

Authors:  Francesco Di Virgilio
Journal:  Cancer Res       Date:  2012-10-22       Impact factor: 12.701

View more
  55 in total

Review 1.  Necroptosis: A new way of dying?

Authors:  Britt Hanson
Journal:  Cancer Biol Ther       Date:  2016-07-19       Impact factor: 4.742

2.  A new perspective of mechanosensitive pannexin-1 channels in cancer metastasis: clues for the treatment of other stress-induced diseases.

Authors:  Di Wu; Lanfang Li; Linxi Chen
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-03-29       Impact factor: 3.848

Review 3.  Targeting liver X receptors in cancer therapeutics.

Authors:  Chin-Yo Lin; Jan-Åke Gustafsson
Journal:  Nat Rev Cancer       Date:  2015-03-19       Impact factor: 60.716

4.  Liver X receptors as potential targets for cancer therapeutics.

Authors:  Xiaoli Ju; Pan Huang; Miao Chen; Qiang Wang
Journal:  Oncol Lett       Date:  2017-10-23       Impact factor: 2.967

5.  LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis.

Authors:  Adam Ceroi; David Masson; Anne Roggy; Christophe Roumier; Cécile Chagué; Thierry Gauthier; Laure Philippe; Baptiste Lamarthée; Fanny Angelot-Delettre; Francis Bonnefoy; Sylvain Perruche; Sabeha Biichle; Claude Preudhomme; Elisabeth Macintyre; Laurent Lagrost; Francine Garnache-Ottou; Philippe Saas
Journal:  Blood       Date:  2016-10-04       Impact factor: 22.113

6.  Pan-cancer analyses of the nuclear receptor superfamily.

Authors:  Mark D Long; Moray J Campbell
Journal:  Nucl Receptor Res       Date:  2015-12-15

Review 7.  Connexin and pannexin signaling in gastrointestinal and liver disease.

Authors:  Michaël Maes; Sara Crespo Yanguas; Joost Willebrords; Bruno Cogliati; Mathieu Vinken
Journal:  Transl Res       Date:  2015-05-16       Impact factor: 7.012

Review 8.  Pyroptosis, a target for cancer treatment?

Authors:  Ying Huang; Jian-Wei Wang; Jiao Huang; Lu Tang; Yun-Hua Xu; Hong Sun; Jie Tang; Guo Wang
Journal:  Apoptosis       Date:  2022-01-22       Impact factor: 4.677

9.  The lipogenic LXR-SREBF1 signaling pathway controls cancer cell DNA repair and apoptosis and is a vulnerable point of malignant tumors for cancer therapy.

Authors:  Bo Yang; Bin Zhang; Zhifei Cao; Xingdong Xu; Zihe Huo; Pan Zhang; Shufen Xiang; Zhe Zhao; Chunping Lv; Mei Meng; Gaochuan Zhang; Liang Dong; Shucheng Shi; Lan Yang; Quansheng Zhou
Journal:  Cell Death Differ       Date:  2020-03-06       Impact factor: 15.828

Review 10.  The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease.

Authors:  Michael B Fessler
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.